HOME >> MEDICINE >> NEWS
Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan

Bridgewater, NJ, November 4, 2003 Researchers have presented updated data comparing DOXIL/CAELYX (doxorubicin HCl liposome injection) to topotecan HCl in patients with recurrent ovarian cancer. These data, from a randomized, controlled, multi-center, open-label, Phase III clinical study, were presented during a poster session at the 12th meeting of the Federation of European Cancer Societies (ECCO 12) in Copenhagen, Denmark.1

The National Cancer Institute estimates that in 2003, 25,000 American women will be diagnosed with ovarian cancer, and 14,000 women will die from it.2 This analysis compared DOXIL and topotecan another common treatment for recurrent ovarian cancer in epithelial ovarian cancer patients whose disease recurred after or did not respond to first-line, platinum-based chemotherapy. The primary objective of this long-term follow up analysis was to measure the overall survival and progression-free survival of these patients.

Researchers reported the median overall survival was three weeks longer for patients treated with DOXIL compared to those treated with topotecan (63 and 60 weeks, respectively, HR 0.82 [95 percent CI = 0.68 to 1.00]; p = 0.05). In addition, the overall progression-free survival was 16.1 weeks for DOXIL compared to 17.0 weeks topotecan (HR 0.88 [95 percent CI = 0.73 to 1.06]; p = 0.171).

Among platinum-sensitive patients (those who had a PFS interval of greater than six months after first-line, platinum-based chemotherapy), the median survival of patients receiving DOXIL was 112 weeks versus 77 weeks for patients receiving topotecan (HR 0.63 [95 percent CI = 0.47 to 0.85]; p = 0.002). DOXIL patients also saw a significant advantage in median PFS versus those receiving topotecan (28.9 and 23.1 weeks, respectively, HR = 0.76 [95 percent CI = 0.58 to 1.00]; p = 0.046).

In the subset of patients with platinum-refractory disease (those whose disease progressed during in
'"/>


4-Nov-2003


Page: 1 2 3

Related medicine news :

1. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
2. Updated press release to October 2004 Cochrane Review
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. Multi-center trial compares three medications in patients with heart failure
6. Study compares overnight dialysis to treatment in centers
7. Study compares clinical diagnoses and autopsy diagnoses in ICU deaths
8. New Commonwealth Fund analysis compares candidtes health care reform proposals
9. Study compares three weekly regimens of chemotherapy for lung cancer
10. Lung cancer screening trial compares CT and standard x-ray
11. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

Post Your Comments:
(Date:4/18/2015)... Carinsurancehints.com has released a new blog post ... offer financial protection against fire damage. , Clients can ... case their vehicle is set intentionally on fire. This type ... or by other things. , It is possible to ... website http://www.carinsurancehints.com/ , in just a few minutes. ...
(Date:4/18/2015)... "I wanted to live a ... healthful juice that contained essential vitamins, minerals and ... increases my energy, improves skin elasticity and gives ... Tapp's Juice to contain fruits, vegetables and other ... and mental fatigue. It features a great taste. ...
(Date:4/18/2015)... April 18, 2015 Insuranceautoquote.info has released ... online auto insurance quotes . , Clients can ... single website. The online environment provides important advantages for ... , Drivers who do not have coverage for ... during any season, day or hour. Many agencies offer ...
(Date:4/18/2015)... 18, 2015 Lower-auto-insurance.com has released a ... auto insurance quotes . , Drivers can ... comparing quotes. A professional insurance brokerage website can help ... in a simple, convenient way. The whole process is ... , Comparing online car insurance quotes is advantageous ...
(Date:4/18/2015)... 2015 Thousand of DePuy Pinnacle hip ... individuals who were allegedly harmed by a metal-on-metal version ... in the U.S. District Court, Northern District of Texas. ... has amended an earlier Case Management Order to allow ... the new amendment permits the claims of up to ...
Breaking Medicine News(10 mins):Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
(Date:4/17/2015)... DALLAS , April 17, 2015 ... report 2015 Market Research Report on Global and ... This is a professional and the deep ... the report introduces Lysine basic information including definition, ... overview (such as US, Europe ...
(Date:4/17/2015)... 2015 CVS Health Corporation (NYSE: CVS ... May 1, 2015, at 8:30 a.m. (EDT) with analysts ... An audio webcast of the conference call ... of the CVS Health website for all interested parties. ... webcast will be archived and available on the web ...
(Date:4/17/2015)... , April 17, 2015  Trovagene, Inc., ... announced today that clinical data presented at the ... its urine-based Precision Cancer Monitoring ℠ (PCM) ... monitoring of EGFR T790M mutations in ... Detection of EGFR T790M Mutation in Urinary Circulating ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
Cached News: